🔗 Share this article

An top health officer has been taken off from oversight in a key research project into hormone suppressants after claims regarding partiality surfaced.

Alleged Involvement Caused Study Suspension

According to news reports, Professor Jacob George, the chief medical director at the medicines regulator, raised worries that led to the halting of the government-funded clinical study in the winter.

The regulator declared on Saturday how the professor was recusing him from any role in the study once gender-critical social media remarks made last year emerged.

Nature Regarding the Social Media Posts

In one post, he referred to author J.K. Rowling as a “treasure of this era.” Elsewhere, the professor remarked that the rejection to accept basic scientific reality is concerning” regarding debates about a elite athlete’s sex.

This agency clarified how while the posts occurred before his official position, he had been removed from involvement with the study as an precaution.

Details of the Paused Pathways Study

This Pathways trial, which was intended to evaluate the impact of puberty blockers for adolescents questioning their own gender identity, was set to commence enrolling subjects during the start of the year.

However, it was suspended in February after its medicines regulator expressed concerns regarding the wellbeing for young participants involved.

• The youngest subjects were projected to be ten to eleven among biological females while 11 to 12 for assigned male at birth.
• The research organizers stated at the time how the thorough screening procedure suggested participants would almost certainly be more mature.
• However, officials has now stated the lowest age threshold must be 14 due to an uncertain potential” for lasting biological harms.”

The study had planned to recruit an estimated two hundred and twenty-six adolescents during the coming three years.

Background Following the Cass Review

This study was initiated subsequent to a recommendation by an independent inquiry on youth gender care, that concluded how the robustness of studies suggesting to show the benefits of this type of medication for adolescents with gender incongruence were low-quality.”

Dr Hilary Cass, who chaired the review, had earlier stated her report exposed a notably limited evidence base” for the benefits of puberty blockers.

She noted, “given that there exist clinicians, young people and families who believe passionately of the positive outcomes, a trial was the necessary step ahead to make sense of the situation.”

Expert Concern of the Decision

Dr Max Davie, an expert in adolescent medicine, said there existed no compelling scientific reason to suspend the research.

“The online comments by Professor George provide an obvious insight into his individual stance regarding gender identity,” Dr. Davie said. “He is entitled to hold any opinions on this subject he chooses, but what is unacceptable would be to permit these opinions to influence the execution of his official role.”

He added: “For clarity, there exists no definitive research justification to stop the Pathways trial. While the professor’s individual beliefs are not the sole plausible cause for the MHRA’s unexpected volte-face, they is the sole instance for which supporting information.”

Regulator Statement and Future Actions

A MHRA spokesperson stated: “With all clinical trials, the MHRA’s primary concern remains the protection and wellbeing for the trial participants. As part of that commitment, complex clinical trials are kept continuously being monitored and the MHRA keeps an ongoing conversation alongside trial sponsors.”

“We has world-class scientific, medical and oversight professionals that operate in a cross-functional group to make research-informed decisions regarding clinical trials. These individuals shall persist to meet alongside the organizers to work through the next steps productively.”

“After the identification of social media posts posted before his tenure began, Professor Jacob George has been recused of continued participation with this clinical trial as a precaution.”